Dirk P Dittmer
Area of interest
25% of human cancers worldwide are infection associated. Our efforts seek to combine translational studies on Kaposi sarcoma and viral lymphoma with genetically engineered mouse models and the detailed molecular investigation of key viral oncogenes. These include microRNAs. We employ high-throughput real-time qPCR and NextGen sequencing as the signature technology platform and are able to rapidly cross-validate the results of experimental approaches into clinical trials.
Secondly, we are actively engaged in the search for new cancer-associated viruses, for instance in cancers which are frequent in low and medium income countries as part of global oncology efforts.
Awards and Honors
- Co-Director UNC Lineberger program in global cancer
- Director UNC Vironomics Core (https://www.med.unc.edu/vironomics)
- Member NCI AIDS-associated malignancies working group
- Member UNC Center for AIDS research (CfAR)
- Member NIDCR Oral HIV/AIDS Research Alliance (OHARA)
- Chair of network laboratories for the AIDS malignancies clinical trials consortium (AMC)
- Chair NIH review panel of AIDS associated opportunistic infections and cancer (AOIC)
NCT01352117 - Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma ;
NCT01435018 - Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS